Denosumab, a fully human monoclonal antibody to RANKL, decreases bone remodeling,
increases bone density, and reduces the risk of fracture. This study compared the inhibitory
effects of denosumab and bisphosphonate on bone resorption. The rate of change in TRACP-5b
levels was significantly higher in denosumab-treated subjects than in bisphosphonate-treated
subjects. These preliminary results suggest that denosumab has potential as an effective
treatment for patients diagnosed with osteoporosis with high serum levels of TRACP-5b and a
previous history or radiological evidence of osteoporotic fracture or high risk of fracture.
抄録全体を表示